Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Sanofi Exubera Effective For Both Type 1 And Type 2 Diabetes, Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee rejects FDA contention that inhaled insulin may not have shown intensive glycemic control in Type 1 diabetes.

You may also be interested in...



Pfizer’s Exubera Launch Now Slated For July

The company had previously said that the inhaled insulin would be available in June; it was approved in January.

Pfizer’s Exubera Launch Now Slated For July

The company had previously said that the inhaled insulin would be available in June; it was approved in January.

Pfizer Breathes Easy: FDA Approves Exubera

Pfizer's Exubera is the first inhaled insulin to clear FDA; labeling recommends lung function testing.

Related Content

Topics

UsernamePublicRestriction

Register

PS063004

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel